Total Cohort, n = 62 | Rituximab, n = 28 | Cyclophosphamide, n = 34 | P | |
---|---|---|---|---|
PFT | ||||
FVC (% predicted value) | 63 (45–75) | 64 (54–91) | 53 (43–64) | 0.036 |
FEV1 (% predicted value) | 62 (46–69) | 63 (51–72) | 56 (44–64) | 0.18 |
TLC (% predicted value) | 63 (47–78) | 68 (52–82) | 55 (44–68) | 0.23 |
cDLCO (% predicted value) | 39 (24–52) | 45 (31–57) | 32 (24–39) | 0.01 |
Dyspnea (NYHA) | 3 | 3 | 3 | 0.1 |
CT scan patterns, % (n) | ||||
NSIP | 66 | 78 (22) | 56 (19) | 0.13 |
OP | 5 | 4 (1) | 6 (2) | 0.88 |
UIP | 8 | 0 | 14 (5) | 0.33 |
NSIP/OP | 21 | 18 (5) | 24 (8) | 0.71 |
Values are median (Q1–Q3) unless otherwise specified. cDLCO: corrected diffusing lung capacity for carbon monoxide; CT: computed tomography; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; ILD: interstitial lung disease; NSIP: nonspecific interstitial pneumonia; NYHA: New York Heart Association; OP: organized pneumonia; PFT: pulmonary function test; TLC: total lung capacity; UIP: usual interstitial pneumonia.